Publicaciones científicas

Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy

Arredondo J, Baixauli J, Beorlegui C, Arbea L, Rodríguez J, Sola JJ, Chopitea A, Hernández-Lizoáin JL.
1 Department of General Surgery, Clínica Universidad de Navarra, Pamplona, Spain
2 Department of Histology and Pathology, School of Medicine, University of Navarra, Pamplona, Spain
3 Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain
4 Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain
5 Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain

Revista: Diseases of the Colon and Rectum

Fecha: 01/04/2013

Oncología Médica Oncología Radioterápica Cirugía General y Digestiva Anatomía Patológica Área de Tumores de Tubo Digestivo

BACKGROUND
Neoadjuvant chemoradiotherapy followed by total mesorectal excision has improved the outcome of locally advanced rectal carcinoma.

OBJECTIVE
The aim of this study was to identify independent prognosis factors of disease recurrence in a group of patients treated with this approach.

DESIGN AND PATIENTS
This study was retrospective in design. Data from patients with locally advanced rectal cancer who had completed treatment from 2000 to 2010 were reviewed.

SETTINGS
The analysis was performed in a tertiary referral center.

MAIN OUTCOME MEASURES
The primary outcomes measured were the recurrence risk factors.

RESULTS
The cohort consisted of 228 patients; 69.3% of them were men, and median age was 59 years. Stage III rectal cancer was found in 64.9% of patients. The most frequently administered therapy was concurrent capecitabine, oxaliplatin, and 7-field radiotherapy, followed by 3-field radiotherapy and fluoropyrimidines. After a median follow-up of 49 months, 23.7% of the patients experienced disease recurrence: 2.6% had local recurrence, 21.1% had distant metastases, and 0.5% had both. Factors significantly correlated with recurrence risk in multivariate logistic regression were y-pathological stage (III vs I/II: OR = 2.51), tumor regression grade (1/2 vs 3+/4: OR = 3.34; 3 vs 3+/4: OR = 1.20), and low rectal location (OR = 2.36). The only independent prognosis factor for liver metastases was tumor regression grade (1/2 vs 3+/4: OR = 4.67; 3 vs 3+/4: OR = 1.41), whereas tumor regression grade (1-2 vs 3+/4: OR = 5.5; 3 vs 3+/4: OR = 1.84), low rectal location (OR = 3.23), and previous liver metastasis (OR = 7.73) predicted lung recurrence.

LIMITATIONS
This is a single institutional experience, neoadjuvant combined therapy is not homogeneous, and the analysis has been performed in a retrospective manner.

CONCLUSIONS
Patients with low third locally advanced rectal cancer with a poor response to neoadjuvant chemoradiotherapy (high y-pathological stage or low tumor regression grade) are at high risk of recurrence. Intense surveillance and the design of alternative therapeutic approaches aimed to lower the distant failure rate seem warranted.

CITA DEL ARTÍCULO   2013 Apr;56(4):416-21. doi: 10.1097/DCR.0b013e318274d9c6

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra